# OnCo record paper-rizvi-mutational-landscape-pd1-science-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rizvi-mutational-landscape-pd1-science-2015" ;
  schema:name "Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer"@en ;
  schema:description "Lung cancers with more mutations, typically those caused by smoking, were more likely to respond to pembrolizumab, the study that established tumour mutational burden as a biomarker for immunotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1126/science.aaa1348> ;
  schema:sameAs <https://doi.org/10.1126/science.aaa1348> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Rizvi NA, Hellmann MD, Snyder A, et al." ;
  onco:related <https://onco.cc/key-papers/paper-pardoll-immune-checkpoint-blockade-nrc-2012/>, <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/wes-wgs/>, <https://onco.cc/technologies/tmb-testing/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/>, <https://onco.cc/pathways/mutagenesis-signatures/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/mutational-signature/> .
